Physician profile
Richard E Young
NPI 1417371881
$10,368.04
in general payments reported to CMS, 2019-2025
17 companies · $2,712 in 2025
The $2,712 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,579 · 2022: $1,869 · 2023: $2,415 · 2024: $1,793 · 2025: $2,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,573 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,573.44 |
| Education | $346.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,856.15 | 2021-2025 | Invega Sustenna, Invega Trinza, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,536.18 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,447.07 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,141.16 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,130.14 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $673.79 | 2021-2025 | Ingrezza |
| Indivior INC. | $463.60 | 2021-2024 | Perseris |
| Alkermes, INC. | $377.74 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $336.68 | 2022-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $335.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $318.73 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $205.72 | 2021-2022 | |
| Corium, LLC | $181.64 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $157.08 | 2021-2022 | |
| Axsome Therapeutics, INC. | $152.77 | 2023-2025 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $38.31 | 2021 | |
| Luye Pharma (USA) LTD. | $15.88 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.